

# Qusai Al-Share, R.Ph, Ph.D.

## *Curriculum Vitae*

Assistant Professor of Pharmacology & Therapeutics

Dept. of Clinical Pharmacy, Faculty of Pharmacy

Jordan University of Science and Technology

Irbid, 22110 Jordan

Phone: +962-2-7201000 Ext. 23767

Office: M5 L-4

Email: [Qyshare@just.edu.jo](mailto:Qyshare@just.edu.jo)

---

### **SUMMARY:**

Assistant Professor of Pharmacology and Therapeutics and distinguished clinical research expert with over 18 years of experience spanning academia and the pharmaceutical industry, with deep expertise in the design, oversight, and execution of global Phase I–IV clinical trials. Former Director of Clinical Research at Novartis Institutes for Biomedical Research (NIBR) New Jersey, USA, led the strategic development and operational delivery of over 32 global clinical trials across key therapeutic areas. A proven contributor to multiple FDA- and EMA-approved therapies, with a strong focus on trial quality, regulatory compliance, and risk-based oversight. Actively engaged in GCP training and clinical research capacity-building, with a strong publication record and commitment to advancing drug development standards. Research focuses on clinical research, medication safety, drug-induced metabolic disorders, and cardiovascular complications, with over 20 peer-reviewed publications in high-ranking international journals.

---

### **EDUCATION**

Ph.D.	<b>Pharmacology and Therapeutics</b> University of Toledo, Ohio, USA	2002-2007
B.S Pharm	<b>B.S Pharmacy</b> Jordan University of Science and Technology, Jordan	1990-1995

### **FELLOWSHIP TRAINING**

Fellowship	<b>Postgraduate Fellowship, Clinical Pharmacology and Drug Development</b> University at Buffalo (State University of New York, SUNY) and Novartis Pharmaceuticals, Inc., New Jersey, USA	2008-2010
------------	---	-----------

### **CERTIFICATION**

<b>Foreign Pharmacy Graduate Examination Committee Certification (FPGEC, USA)</b>	2004
<b>Teaching and Learning Program Certificate</b> School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, SUNY Pharmacy Residents and Fellows Teaching and Learning Program Certificate	2008-2009
<b>Medication Therapy Management (MTM) Certificate</b> National Certificate Training Program Comprehensive Instruction in Strategy, Procedure and Clinical Application of MTM	Sep 2019

### **LICENSURE**

Pennsylvania State Board of Pharmacy, USA (License #: RP444112, Inactive)	2010
Multistate Pharmacy Jurisprudence Examination (MPJE), Pennsylvania, USA	2010
Ohio State Board of Pharmacy, USA (License #: RPH 0322844-2)	2008
Multistate Pharmacy Jurisprudence Examination (MPJE), Ohio, USA	2008

American Board of Pharmacy (NABP)	2008
North America Pharmacist Licensure Examination (NAPLEX)	2008
Registered Pharmacist, Jordan	1995

### **POSITIONS AND ACADEMIC APPOINTMENTS**

<b>Assistant Professor of Pharmacology &amp; Clinical Pharmacy</b>	2017-Present
--	--------------

Dept. of Clinical Pharmacy, Faculty of Pharmacy  
Jordan University of Science and Technology  
Irbid, Jordan

<b>Adjunct Faculty, Master of Clinical Research (MCR) Program</b>	2016-Present
---	--------------

Massachusetts College of Pharmacy (MCPHS)  
Dept. of Pharmaceutical Sciences, Clinical Research  
Boston, USA

<b>Senior Clinical Research Scientist</b> (Clinical Trials Leader)	2009-2017
--	-----------

Translational Medicine, Novartis Institutes for Biomedical Research, East Hanover, NJ, USA

<b>Clinical Instructor/Adjunct Faculty</b>	2008-2010
--	-----------

School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, SUNY  
Buffalo, NY, USA

<b>Postdoctoral Fellow</b>	2008-2009
----------------------------	-----------

School of Pharmacy & Pharmaceutical Sciences, SUNY Buffalo and  
Novartis Pharmaceuticals Inc. USA

<b>Pharmacy Intern and Registered Pharmacist</b>	2007-2008
--	-----------

Rite Aid Pharmacy, Canton, Ohio, USA

<b>Graduate Research Assistant, Graduate</b>	2002-2007
--	-----------

University of Toledo, College of Medicine, Department of Pharmacology  
Toledo, OH, USA

<b>Team Leader and Senior Medical Representative</b>	1998-2002
--	-----------

Sanofi Pharmaceuticals Inc., Jordan

<b>Pharmacist in charge</b>	1995-1998
-----------------------------	-----------

Alsharei Pharmacy, Jordan

### **TEACHING EXPERIENCE**

Courses taught at Jordan University of Science and Technology, Irbid, Jordan	(2017-Present):
--	-----------------

#### **Undergraduate and PharmD Courses:**

PHAR/PHMD 242	Pharmacology 1 (Introduction to Pharmacology and CNS Pharmacology)
PHAR/PHMD 343	Pharmacology 2 (cardiovascular, respiratory, GIT, NSAIDs)
PHMD 443	Therapeutics (Neurological and Psychiatric Disorders)
PHMD 544	Therapeutics (Woman and Man Health)
PHMD 560	Therapeutics 3 (Kidney, Liver, Geriatric and Pediatric Diseases)
PHMD 568	Clinical Seminar (1) and (2)

PHMD 401	Community Pharmacy Training (for PharmD Students)
PHMD 402	Community Pharmacy Training (for BS Pharmacy Students)
PHMD 505	Selected Topics in Clinical Pharmacy
PHMD 548	Comprehensive Therapeutics (for PharmD Students)
PHMD 675	Clinical Pharmaceutical Research (for PharmD Students)
PHMD 643	Clinical Training (Internal Medicine)
PHMD 644	Clinical Training (Pediatric Diseases)
PHMD 676	Clinical Training (Disease State Management)
PHAR 466	Ethics and Pharmacy Practice

**Graduate Level Courses:**

PHAR 700	Scientific Writing and Research Ethics
PHAR 704	Clinical Practice 1
PHAR 741	Therapeutics for MS Students (CNS module)
PHAR 744	Comprehensive Therapeutics, MS Pharmacy Students
PHAR 707	Clinical Training (Internal Medicine)
PHAR 771	Principles of Experimental Therapeutics
PHAR 737	Clinical Pharmacology

Courses Taught at Massachusetts College of Pharmacy & Health Sciences (MCPHS), Boston, USA:

**Online Graduate Courses (Master of Clinical Research):**

MCR 802O	Research Methodology & the Development of Protocols & Proposals
MCR 804O	Graduate Project in Clinical Research

Supervised Capstone Projects (graduation project) for over 150 MS Students (Graduate Project in Clinical Research), Massachusetts College of Pharmacy and Health Sciences 2016-

**RESEARCH EXPERIENCE****Research Interests**

- Drug-related problems, inappropriate medication prescribing and medication safety
- Mechanisms of insulin resistance in type 2 diabetes mellitus and obesity, and related cardiovascular complications
- Drug-induced insulin resistance
- Drug development and clinical research (clinical study design, protocol writing, clinical trial conduct, drug safety review, medical monitoring, data presentation and study reporting)

**Research Positions Held**

**Director of Clinical Research (Senior Clinical Research Scientist)** 2010-2017

Novartis Institutes for Biomedical Research (NIBR), East Hanover, New Jersey, USA

- Led Clinical research projects in cardiovascular and metabolic diseases

**Postdoctoral Research Fellow** 2008-2010

University of Buffalo and Novartis Institute for Biomedical Research, USA

- Clinical Research and Drug Development training
- Insulin action and anti-inflammatory drugs
- Pharmacokinetics and pharmacodynamics (PK/PD)

**Predoctoral Research Fellow**

2002-2007

Department of Pharmacology and Therapeutics, University of Toledo, OH, USA

- Research project in molecular mechanisms of insulin resistance and cardiovascular complications
- Developed an insulin resistance model to test for abnormal insulin action in the pre-diabetic state

**CLINICAL TRIALS LEADERSHIP**

Clinical development lead on over 32 global multicenter, multicountry clinical trials (Phases 1-4). Role included study planning, design, protocol writing, conduct oversight, safety and efficacy data ongoing review, medical monitoring, results reporting and presentation.

- 13 clinical trials in cardiovascular disease area
- 9 clinical trials in ophthalmology
- 5 clinical trials respiratory/rare diseases
- 2 clinical trials in endocrinology
- 1 clinical trial each in neurology, nephrology, rare disease/immunology

**RESEARCH FUNDING****Ongoing Projects**

1. **Qusai Al-Share** (PI), Mohammad Alsaggar (Co-PI). 2020-2021. Role of CEACAM1 in Olanzapine-Induced Obesity and Metabolic Disturbances. Sponsor: Deanship of Research, Jordan University of Science and Technology. **Amount: \$13,700.**
2. **Qusai Al-Share** (PI), Mohammad Alsaggar (Co-PI). 2021-2022. Effect of Olanzapine treatment on the mRNA levels of hepatic CEACAM1 in male mice. Sponsor: Deanship of Research, Jordan University of Science and Technology. **Amount: \$14,122.**
3. **Qusai Al-Share** (PI), Mohammad Alqudah (Co-PI). 2021-2022. An Observational, Retrospective, Cross-sectional Study to Evaluate Medication Appropriateness in Older Adults with Polypharmacy. Sponsor: Deanship of Research, Jordan University of Science and Technology. **Amount: \$6,213.**
4. **Qusai Al-Share** (PI), 2022-2023. Evaluation of medication appropriateness in older adults in a respiratory outpatient clinic using the medication appropriateness index. **Amount \$565.**
5. **Qusai Al-Share** (PI), 2022-2023, Evaluating Clozapine-induced Obesity and Metabolic Derangements: A Potential Role for the Carcinoembryonic Antigen-related Cell Adhesion Molecule 1. **Amount \$9,178.**
6. **Qusai Al-Share** (PI), Nehad Ayoub (Co-PI), 2022-2023. Evaluation of Medication Appropriateness in Older Diabetic Adults with Polypharmacy: An Observational, Retrospective, Cross-sectional Study. **Amount \$565.**
7. **Qusai Al-Share** (PI), 2024-2025. Potentially inappropriate medication use in older adults with chronic respiratory diseases in an outpatient setting in Jordan. **Amount \$565.**

**HONORS & AWARDS****Novartis Institute for BioMedical Research (NIBR) Team's Award**

Mar 2015

Recognizes and rewards select group of scientists who distinguish themselves in teams by having significant impact on collective drug discovery efforts, Cambridge, MA

<b>ACCP Fellows and Residents Travel Award</b>	Oct 2009
To attend the 2009 ACCP annual meeting in Anaheim, CA	
<b>Best Postdoctoral Fellowship Oral Presentation Award</b>	Jun 2009
School of Pharmacy and Pharmaceutical Sciences, University at Buffalo/Novartis Drug Development Fellowship Research Day, Buffalo, NY	
<b>Liberato J.A. DiDio Award</b>	Apr 2005
Research Excellence (1 <sup>st</sup> Place). The 20 <sup>th</sup> annual Research Forum Graduate School, the University of Toledo. Presented a winning poster entitled "Reduction of Hepatic CEACAM1 Levels: A Mechanism of Insulin Resistance Induced by High-fat Diet"	
<b>Graduate Studies Dean's List</b>	2005
Research Excellence. University of Toledo, College of Medicine, Ohio	
<b>Liberato J.A. DiDio Award</b>	Apr 2004
Research Excellence (2 <sup>nd</sup> Place). The 19 <sup>th</sup> Annual Research Forum Graduate School at the University of Toledo. Presented a winning poster entitled "High-fat Diet Decreases CEACAM1 Levels in Liver".	
<b>Predoctoral Fellowship Award</b>	2002-2007
Predoctoral training research award in Biomedical Sciences. Department of Pharmacology, University of Toledo, OH	
<b>Jordanian Government scholarship award for BS in Pharmacy</b>	1990-1995
School of Pharmacy, Jordan University of Science and Technology	

#### **COURSES AND WORKSHOPS COMPLETED:**

1. ICH/GCP Obligations of Sponsors and Monitors course (GCP04 Ver 4.0), Jul 2025
2. GCP/ICH Obligations of Sponsors and Monitors course (GCP04 Ver 3.3), Jun 2024
3. GxP Training (PHDV61 Ver 1.8) course, May 2023
4. Targeted SDV Subject Management course (MEDS Reporter, Rave EDC, Rave EDC (SIMT), Rave Modules, Rave Architect Roles) course, Apr 2023
5. Medidata Rave EDC: Getting Started course (MEDS Reporter, Rave EDC, Rave EDC (SIMT), Rave Modules, Rave Architect Roles) course, Mar 2023
6. Code of conduct and Business Ethics course (CBT 165-11 Ver 2.0), Aug 2022
7. Effective Communication Workshop, 2021.
8. DISC (Dominance, Influencing, Stabilizing, Cautious) Clinical Development Workshop, Dec 2021
9. Code of conduct and Business Ethics course (CBT 165-11 Ver 1.0), Sep 2021
10. GxP Training (TRAIN-000061 Ver 1.0) course, Jul 2021
11. GCP/ICH Obligations of Sponsors and Monitors course (GCP04 Ver 3.2), Jun 2021
12. Reporting and Handling Misconduct course (CBT-165-07 Ver 1.0) Jun 2021
13. Hiring Healthcare Professionals, Patients and Managed Care Customers, End-to-End Process Training Course (CBT-165-04 Ver 1.0), Jun 2021
14. Good Communication Practices (CBT-165-01 Verr 1.0) May 2021.
15. Social Medica Usage Policy Training course (CBT-140-01 Ver 1.0) Jun 2021
16. Access to and Management of Veeva Vault Training Course (TRAIN-000035- V3.0) May 2021.
17. Electronic Signature Course (NH-00003- Ver 5.0), May 2021

18. "Introduction to cGMP": a training course completed on 26 May 2020.
19. "Medication Therapy Management": a 13-module training course offered by POWER-PAK C.E as part of the Medication Therapy Management Program Certification Program, 2 Sep 2019.
20. "GCP for Clinical Trials with Investigational Drugs and Biologics [ICH Focus]": a 7-module refresher course offered by CITI Program, 8 Jul 2019
21. "GCP for Clinical Trials with Investigational Drugs and Biologics [ICH Focus]": a 15-module basic course offered by CITI Program, 20 Jun 2017
22. "Protocol Writing Workshop": offered by Novartis Pharmaceutical Inc., Jul 2015, Cambridge, Massachusetts, USA
23. "Punctuation for Clarity and Style": a one-day workshop offered by the American Medical Writers Association-the Delaware Valley Chapter, 18<sup>th</sup> Annual Princeton Conference, 26 Apr 2014, Princeton, New Jersey, USA
24. "Writing the Investigator Brochure": a one-day workshop offered by the American Medical Writers Association-the Delaware Valley Chapter, 18<sup>th</sup> Annual Princeton Conference, 26 Apr 2014, Princeton, New Jersey, USA
25. "Freelancing and Beyond, Secrets to LinkedIn Success, A panel on Legal Experts to Address Contract Concerns, Google+ Authorship to Support Your Own Thought Leadership, and Best Practices in Freelancing from Success Freelancers": a one-day workshop offered by the American Medical Writers Association-Delaware Valley Chapter, the 12<sup>th</sup> Annual Freelance Conference, 22 Mar 2014, Philadelphia, Pennsylvania, USA
26. "Global Clinical Trials: Preferred CRO Partnerships": a one-day workshop offered by Opal Events, 1-2 Oct 2012, Philadelphia, Pennsylvania, USA
27. "Influencing for Results": training course offered by Novartis Pharmaceutical Inc., Jul 2011, Cambridge, Massachusetts, USA
28. "Presentation Skills": training course offered by Novartis Pharmaceutical Inc., Jul 2011, Cambridge, Massachusetts, USA
29. "Pediatric Clinical Trials Forum": training course offered by Novartis Pharmaceutical Inc., Jun 2011, East Hanover, New Jersey, USA
30. "Quality Performance": training course offered by Novartis Pharmaceutical Inc., Jul 2011, Cambridge, Massachusetts, USA
31. May 2011
32. "Project Management": training course offered by Novartis Pharmaceutical Inc., May 2011, East Hanover, New Jersey, USA
33. "Drug Development Timelines Today and Tomorrow, The Challenge of Pharmaceutical R&D": a training course offered by Association of Clinical Research Professionals (ACRP), 30 Apr 2011, Seattle, Washington, USA.
34. "IND Submission": training course offered by Novartis Pharmaceutical Inc., Apr 2011, East Hanover, New Jersey, USA
35. "Code of Conduct": training course offered by Novartis Pharmaceutical Inc., Apr 2011, East Hanover, New Jersey, USA
36. "Clinical Trial Application": training course offered by Novartis Pharmaceutical Inc., Feb 2011, East Hanover, New Jersey, USA
37. "GCP" course: a three-day training course on Good Clinical Practice in Clinical Research offered by Novartis Pharmaceutical Inc., Jun 2010, Whippany, New Jersey, USA
38. "Road to PoC": a two-day workshop offered by Novartis Pharmaceuticals to train on proof-of-concept studies, Mar 2010, Whippany, New Jersey, USA
39. "Target to Therapy": A two-day Drug Development training course by Novartis Pharmaceuticals, 18-19 Nov 2009, East Hanover, New Jersey, USA
40. "Basics of Clinical Research": by American College of Clinical Pharmacy, 18 Oct 2009, Anaheim, California, USA.

41. "Application of Modeling over the Development of Life Cycle of Biologics": offered by the American Conference on Pharmacometrics (ACoP), 5 Oct 2009, Ledyard, Connecticut, USA
42. "Development and Utilization of Disease Models": offered by the American Conference on Pharmacometrics (ACoP), 6 Oct 2009, Ledyard, Connecticut, USA

### **TRAINING COURSES AND WORKSHOPS TAUGHT:**

"Clinical Trial Conduct and GCP Overview, a Sponsor Perspective": a one-day course taught at Pharmaceutical Research Center (PRC), 3 Jul 2019, Jordan University of Science & Technology, Irbid, Jordan

"Pharmaceutical Industry: Developing a New Drug": an invited lecture by the NIH at the 5<sup>th</sup> Annual NIH Career Symposium, 18 May 2012, Bethesda, Maryland, USA

### **COMMITTEES AND SERVICE**

#### **Community Service Level:**

- Chair, Jordan National Qualification Framework (JNQF) Course Evaluation for PharmD Program (2023/2024)
- Member, Ministry of Health Committee on Rationale Use of Medications (2023/2024)
- Member, Jordanian Civil Services Bureau for Pharmacists Competency Framework (2022/2023)
- Member, JNIL Technical Scientific Advisory Committee (TAC), Tufts University/USAID (2020/2025)

#### **University Level: Jordan University of Science & Technology**

- Member, University Council, Jordan University of Science & Technology (2022/2023)
- Member, University Council, Jordan University of Science & Technology (2019/2020)

#### **Faculty Level: Faculty of Pharmacy, Jordan University of Science & Technology**

- Member, Student Advisory Committee (2024/2025)
- Member, Student Disciplinary Committee (2024/2025)
- Member, Department Scientific Research Committee (2024/2025)
- Member, Department Examinations Committee (2024/2025)
- Member, MS in Pharmacology and Experimental Therapeutics Evaluation (2023/2024)
- Chair, Curriculum Planning Committee for PhD Program in Pharmaceutical Sciences (2022/2023)
- Member, Scientific Research Committee (2022/2023)
- Chair, Curriculum Planning Committee for MS in Regulatory Affairs, Joint Program with JFDA (2022/2023)
- Chair, Scientific Committee (2022/2023)
- Member, Consultation Committee (2022/2023)
- Member, Pharmacology Curriculum Review Committee (2022/2023)
- Member, Scientific Research Committee (2021/2022)
- Member, Scientific Committee (2021/2022)
- Member, Faculty Members Evaluation Committee (2021/2022)
- Member, Examination Evaluation Committee (2021/2022)
- Member, Distant Learning Committee (2020/2021)
- Member, Examination Evaluation Committee (2020/2021)
- Member, Faculty Members Evaluation Committee (2020/2021)
- Member, Scientific and Continuing Education Committee (2019/2020)
- Member, Conferences and Scientific Days Committee (2019/2020)

- Chair, Accreditation subcommittee for Student Services (2019/2020)
- Member, Scientific, Cultural and Continuing Education Committee (2018/2019)
- Member, Conferences and Scientific Days Committee (2018/2019)
- Member, Scientific and Educational Committee (2017/2018)
- Chair, Conferences and Scientific Days Committee (2017/2018)

### **Academic Supervision and Thesis Committees**

#### **Major Advisor:**

- Asma Mohammad Odat (MSc in Clinical Pharmacy, Fall 2024): Evaluating clozapine-induced obesity and metabolic derangements: a potential role for carcinoembryonic antigen-related cell adhesion molecule type-1. Fall 2024
- Afnan AbuShqair (MSc in Clinical Pharmacy, Fall 2023):
- Lujain Emad Nsour (MSc in Clinical Pharmacy, Fall 2023): Evaluation of medication appropriateness in older diabetic adults with polypharmacy: an observational, retrospective, cross sectional study. Summer 2023.
- Rashed Mohammad Fraij (MSc in Clinical Pharmacy, Spring 2025). Potentially inappropriate medication use in older adults with chronic respiratory diseases in outpatient setting in Jordan.

#### **Co-Advisor:**

- Bayan Abdallah Abandah (MSc in Clinical Pharmacy, Fall 2018). renal failure by orellanine from the poisonous webcap mushroom cortinarius orellanus: mechanism of action. (Fall 2019).
- Salam Sardieh (MSc in Clinical Pharmacy, Fall 2023): Evaluation of the predictive value of blood levels of hepatocyte growth factor and vascular endothelial growth factor in solid cancer patients treated with bevacizumab. (Spring 2024).
- Elaf Rababaah (MSc in Clinical Pharmacy, Fall 2025):

#### **Internal Examiner:**

- Tala Mahmoud Algarram (MSc in Clinical Pharmacy). Cardiac effects of atorvastatin in rat model of streptozotocin-induced diabetes

#### **Other Services**

- Preceptor, Northeastern University School of Pharmacy (Boston) and Novartis Pharmaceuticals Inc. Preceptor for PharmD students during their Co-Op at Novartis Inc., East Hanover, NJ (2010-2014)
- Northeastern University Co-Op internship coordinator, where he was involved in reviewing, selecting and mentoring interns at Novartis Pharmaceuticals Inc., East Hanover, NJ (2010-2014)
- Mentor and group leader for Drug Development Fellowship programs, University at Buffalo, Rutgers University School of Pharmacy and Novartis Pharmaceuticals Inc. Buffalo, NY and East Hanover, NJ (2010-2014)



- Member, Interview and Selection Committee for Fellowship candidates for University at Buffalo, Rutgers University College of Pharmacy and Novartis Fellowship Program, Buffalo, NY and East Hanover, NJ (2009-2014)
- Member, The PharmD Candidate Selection Committee at The University at Buffalo, School of Pharmacy for the class began Fall 2009 (Interviewer of PharmD candidates). Buffalo, NY (2009).
- Member, Clinical Research Track Committee. Served as a reviewer to evaluate PharmD Student Clinical Research Track Projects Defense. Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, NY. (April 15, 2009).

### **JOURNAL REVIEWER**

- |   |              |
|---|--------------|
| • PLOS ONE  | 2024-Present |
| • American Journal of Pharmaceutical Education (AJPE)       | 2008-Present |
| • Clinical Epidemiology                                     | 2020-Present |
| • Acta Scientific Pharmaceutical Sciences (Editorial Board) | 2021-Present |

### **OTHER SKILLS**

- Excellent presentation, organizational, communication and Project management skills
- Proficient in statistical analysis programs (SYSTAT, Sigmaplot, Statview, Prizm, SPSS)

### **PROFESSIONAL MEMBERSHIPS AND ORGANIZATIONS**

- American Pharmacists Association (APhA)
- Ohio Pharmacists Association (OPA)
- Association of Clinical Research Professionals (ACRP)
- The University of Toledo Alumni Association
- The University at Buffalo Alumni Association
- Jordan Pharmacists Association (JPA)

### **FUNDED RESEARCH**

#### **Ongoing Funding:**

- 1- **Qusai Al-Share (PI)** and Mohammad Alsaggar (Co-PI). "Role of CEACAM1 in Olanzapine-Induced Obesity and Metabolic Disturbances". Sponsor: Deanship of Research, Jordan University of Science & Technology. Amount: \$14,124.
- 2- **Qusai Al-Share (PI)** and Mohammad Alsaggar (Co-PI). "Effect of Olanzapine treatment on the mRNA levels of hepatic CEACAM1 in male mice". Sponsor: Deanship of Research, Jordan University of Science & Technology. Amount: \$13,699.
- 3- **Qusai Al-Share (PI)** and Mohammad Alqudah (Co-PI). "An Observational, Retrospective, Cross-sectional Study to Evaluate Medication Appropriateness in Older Adults with Polypharmacy". Sponsor: Deanship of Research, Jordan University of Science & Technology. Amount: \$6,213.

### **PUBLICATIONS**

#### **Peer Reviewed Papers:**

[PubMed](#)

[Google Scholar](#)

[ResearchGate](#)

1. **Al-Share, Q.A.**, Tahrawi A.Y., Khasawneh D.M., Alshare, A.W., Alkhasawneh, S.A. (2025) Retrospective Evaluation of Medication Appropriateness in Older Adults with Hepatic Cirrhosis. *Science Progress*, 108(2), 1-19. <https://doi.org/10.1177/00368504251330037>.

2. **Al-Share, Q.A.**, Khasawneh, R.A., Rababa'h, A.M., Asfar, F.N., Mohammad, Y.N. (2025). Evaluation of medication appropriateness index in cardiovascular outpatient clinic: A cross-sectional study. *Currents in Pharmacy Teaching and Learning*, 17, 102262. <https://doi.org/10.1016/j.cptl.2024.102262>
3. **Al-Share, Q.A.**, Abu Shqair, A.A., Khasawneh, R.A., Albadawi, A.J., Ghneimat, A. (2024). Medication appropriateness in elderly patients with chronic respiratory disease: Insights from the medication appropriateness index. *Pharmacy Practice*, 22(4), 3058. <https://doi.org/10.18549/PharmPract.2024.4.3058>
4. Ayoub, N.M., Sardiah, S., **Al-Share, Q.Y.**, Alkader, M.S. (2024). Exploring angiogenic pathways in breast cancer: Clinicopathologic correlations and prognostic implications based on gene expression profiles from a large-scale genomic dataset. *PLOS ONE*, 19(9), e0310557. <https://doi.org/10.1371/journal.pone.0310557>
5. Alkhatib, A., Nuseir, K., Abdo, N., **Al-Share, Q.**, Altawalbeh, O. (2024). Behavioral interventions with and without pharmacological treatment: A comparative study at an autistic center in Jordan. *Jordan Journal of Pharmaceutical Sciences*, 17(2), 395-406. <https://doi.org/10.35516/jjps.v17i2.1974>
6. Nusair, S.D., Abandah, B., **Al-Share, Q.Y.**, Abu-Qatouseh, L., Ahmad, M.I.A. (2024). Toxicity induced by orellanine from the mushroom *Cortinarius orellanus* in primary renal tubular proximal epithelial cells (RPTEC): Novel mechanisms of action. *Toxicon*, 235, 107312. <https://doi.org/10.1016/j.toxicon.2023.107312>
7. Rashrash, M., Schliesser, S., Shatnawi, A., Sawesi, S., **Al-Share, Q.** (2024). Adverse drug reactions (ADRs) case studies: Moderate ADRs. In *Clinical Case Studies on Medication Safety* (pp. 33-80). Springer. <https://doi.org/10.1016/B978-0-323-98802-5.00005-4>
8. Shatnawi, A., Kamran, Z., **Al-Share, Q.** (2024). Pharmacogenomics of lipid-lowering agents: The impact on efficacy and safety. *Personalized Medicine*, 20(1), 65-86. <https://doi.org/10.2217/pme-2022-0041>
9. Stasi, K., **Al-Share, Q.**, Jain, M., Wald, M., Li, Y. (2024). Topical ocular TRPV1 antagonist SAF312 (Libvatrep) demonstrates safety, low systemic exposure, and no anesthetic effect in healthy participants. *Translational Vision Science & Technology*, 11(11), 15. <https://doi.org/10.1167/tvst.11.11.15>
10. Altawalbeh, S.M., Almomani, B.A., Alefan, Q., Momany, S.M., **Al-Share, Q.Y.** (2024). The influence of adverse drug effects on health-related quality of life in chronic obstructive pulmonary disease patients. *International Journal of Pharmacy Practice*, 30(5), 457-465. <https://doi.org/10.1093/ijpp/riac052>
11. Heinrich, G., Muturi, H.T., Rezaei, K., **Al-Share, Q.Y.**, DeAngelis, A.M., Bowman, T.A., Ghadieh, H.E., Ghanem, S.S., Zhang, D., Garofalo, R.S., Yin, L., Najjar, S.M. (2017). Reduced hepatic carcinoembryonic antigen-related cell adhesion molecule 1 level in obesity. *Frontiers in Endocrinology*, 8 (54):1-5. <https://doi.org/10.3389/fendo.2017.00054>
12. Heinrich, G., Ghadieh, H.E., Ghanem, S.S., Muturi, H.T., Rezaei, K., **Al-Share, Q.Y.**, Bowman, T.A., Zhang, D., Garofalo, R.S., Yin, L., Najjar, S.M. (2017). Loss of hepatic CEACAM1: A unifying mechanism linking insulin resistance to obesity and non-alcoholic fatty liver disease. *Frontiers in Endocrinology*, 26 (8): 8. <https://doi.org/10.3389/fendo.2017.00008>

13. Russo, L., Ghadieh, H.E., Ghanem, S.S., **Al-Share, Q.Y.**, Smiley, Z.N., Gatto-Weis, C., Esakov, E.L., McInerney, M.F., Heinrich, G., Tong, X., Yin, L., Najjar, S.M. (2016). Role for hepatic CEACAM1 in regulating fatty acid metabolism along the adipocyte-hepatocyte axis. *Journal of Lipid Research*, 57(12), 2112-2123. <https://doi.org/10.1194/jlr.M072066>
14. Flarakos, J., Du, Y., Bedman, T., **Al-Share, Q.Y.**, Jordaan, P., Chandra, P., Albrecht, D., Wang, L., Gu, H., Einolf, H., Heidi, J., Huskey, S., Mangold, J.B. (2016). Disposition and metabolism of [<sup>14</sup>C] Sacubitril/Valsartan (formerly LCZ696) an angiotensin receptor neprilysin inhibitor, in healthy subjects. *Xenobiotica*, 46(11), 1011-1023. <https://doi.org/10.3109/00498254.2015.1014944>
15. Ramakrishna, S.K., Khuder, S.S., **Al-Share, Q.Y.**, Russo, L., Abdallah, S.L., Patel, P.R., Heinrich, G., Muturi S.K., Oyarce, A.M., Shah, Y.M., Sanchez, E.R., and Najjar, S.M. (2016). PPAR $\alpha$  (Peroxisome Proliferator-activated Receptor  $\alpha$ ) activation reduces hepatic CEACAM1 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-1) expression to regulate fatty acid oxidation during fasting-refeeding transition. *Biological Chemistry*, 291 (15): 8121-9. <https://doi.org/10.1074/jbc.m116.714014>
16. Li, C., Culver, S., Quadri, S., Ledford, K., **Al-Share, Q.Y.**, Ghadieh, H., Najjar, S., Siragy, H. (2015). High-fat diet amplifies renal renin angiotensin system expression, blood pressure elevation and renal dysfunction caused by Ceacam1 null deletion. *American Journal of Physiology, Endocrinology and Metabolism*, 309(4), E399-E408. <https://doi.org/10.1152/ajpendo.00158.2015>.
17. **Al-Share, Q.Y.**, DeAngelis, A.M., Lester, S.G., Bowman, T.A., Ramakrishnan, S.K., Abdallah, S.L., Russo, L., Patel, P.R., Kaw, M.K., Raphael, C.K., Kim, A.J., Heinrich, G., Lee, A.D., Kim, J.K., Kulkarni, R.N., Philbrick, W.M., Najjar, S.M. (2015). Forced hepatic overexpression of CEACAM1 curtails diet-induced insulin resistance. *Diabetes*, 64(9), 2974-2984. <https://doi.org/10.2337/db14-1772>
18. Lester, S.G., Russo, L., Ghanem, S.S., Khuder, S., DeAngelis, A.M., Esakov, E.A., Bowman, T.A., Heinrich, G., **Al-Share, Q.Y.**, McInerney, M.F., Philbrick, W.M., Najjar, S.M. (2015). Hepatic CEACAM1 over-expression protects against diet-induced fibrosis and inflammation in white adipose tissue. *Frontiers in Endocrinology*, 3 (6): 116. <https://doi.org/10.3389/fendo.2015.00116>
19. Haram, P.M., Kemi, O.J., Lee, S.J., Bendheim, M.Ø., **Al-Share, Q.Y.**, Waldum, H.L., Bakke, I., McInerney, M.F., Koch, L.G., Britton, S.L., Najjar, S.M., Wisloff, U. (2009). Aerobic interval training vs. continuous moderate exercise in the metabolic syndrome of rats artificially selected for low aerobic capacity. *Cardiovascular Research*, 81(4), 723-732. <https://doi.org/10.1093/cvr/cvn332>
20. Lee, S.J., Heinrich, G., Fedorova, L., **Al-Share, Q.Y.**, Ledford, K.J., Fernstrom, M.A., McInerney, M.F., Erickson, S.K., Gatto-Weis, C., Najjar, S.M. (2008). Development of nonalcoholic steatohepatitis in insulin-resistant liver-specific S503 carcinoembryonic antigen-related cell adhesion molecule mutant mice. *Gastroenterology*, 135(6), 2084-2095. <https://doi.org/10.1053/j.gastro.2008.08.007>
21. Tjønnå, A.E., Lee, S.J., Rognmo, Ø., Stølen, T., Bye, A., Haram, P.M., Loennechen, J.P., **Al-Share, Q.Y.**, Skogvoll, E., Slørdahl, S.A., Kemi, O.J., Najjar, S.M., Wisloff, U. (2008). Aerobic interval training versus continuous moderate exercise as a treatment for the metabolic syndrome: A pilot study. *Circulation*, 118(3), 346-354. <https://doi.org/10.1161/CIRCULATIONAHA.108.772822>
22. Najjar, S.M., Yang, Y., Fernstrom, M.A., Lee, S.J., DeAngelis, A.M., Abou-Rjaily, G.A., **Al-Share, Q.Y.**, Dai, T., Miller, T.A., Ratnam, S. (2005). Insulin acutely decreases hepatic fatty acid synthase activity. *Cell Metabolism*, 2(1), 43-53. <https://doi.org/10.1016/j.cmet.2005.06.001>

23. Wisloff, U., Najjar, S.M., Ellingsen, O., Haram, P.M., Swoap, S., **Al-Share, Q.Y.**, Fernstrom, M., Rezaei, K., Lee, S.J., Koch, L.G., et al. (2005). Cardiovascular risk factors emerge after artificial selection for aerobic capacity. *Science*, 307(5708), 418-420. <https://doi.org/10.1126/science.1108177>
24. Abou-Rjaily, G.A., Lee, S.J., May, D., **Al-Share, Q.Y.**, DeAngelis, A.M., Ruch, R.J., Neumaier, M., Kalthoff, H., Lin, S.H., Najjar, S.M. (2004). CEACAM1 modulates epidermal growth factor receptor-mediated cell proliferation. *Journal of Clinical Investigation*, 114(7), 944-952. <https://doi.org/10.1172/JCI21786>
25. Dai, T., Abou-Rjaily, G.A., **Al-Share, Q.Y.**, Yang, Y., Fernstrom, M.A., DeAngelis, A.M., Lee, A.D., Sweetman, L., Amato, A., Pasquali, M., et al. (2004). Interaction between altered insulin and lipid metabolism in CEACAM1-inactive transgenic mice. *Journal of Biological Chemistry*, 279(44), 45155-45161. <https://doi.org/10.1074/jbc.m404764200>

#### Non-Peer Reviewed Papers:

1. **Al-Share, Q.Y.**, Cirincione, B., and Mager, D.E. A Focus on Type 2 Diabetes Mellitus. *American Association of Pharmaceutical Scientists (AAPS) NEWSMAGAZINE*, December 2008, pp: 19-24).

#### **ORAL PRESENTATIONS**

1. Evaluation of Medication Appropriateness in Older Patients Diagnosed with Chronic Respiratory Disease in Outpatient Setting". (April 25, 2024) 1st International Pharmaceutical Sciences Conference. Faculty of Pharmaceutical Sciences, Hashemite University, Zarka, Jordan.
2. Industry: Developing a New Drug (May 18, 2012). Fifth Annual NIH Career Symposium, National Institute of Health, Bethesda, MD
3. The effect of food on drug pharmacokinetics: a pharmaceutical industry perspective (June 1, 2010). University at Buffalo, Buffalo, NY
4. Anti-inflammatory Effects of Insulin as Compared to Four Systemic Corticosteroids (June 5, 2009). University at Buffalo/Novartis Fellowship Research Day. School of Pharmacy and Pharmaceutical Sciences, the State University of New York at Buffalo
5. Pharmacy Residency and Fellowship Training, Topics in Health Systems Pharmacy Practice (Course PHM 529) (Sep 2008), School of Pharmacy and Pharmaceutical Sciences, the State University of New York at Buffalo
6. Tools for Succeeding in Graduate School (Jun 2005). Summer Undergraduate research Fellowship (SURF) Program. Medical University of Ohio, Toledo, OH
7. Reduction of Hepatic CEACAM1 Levels: A Mechanism of Insulin Resistance Induced by High-fat Diet (Jan 2005 and Jun 2006). The 32<sup>nd</sup> and 33<sup>rd</sup> Annual Pharmacology Research Colloquium at Wayne State University, Detroit, MI and Michigan State University, East Lansing, MI, respectively.
8. Hypolipidemic Agents Improve Fat Metabolism and the Hypolipidemic State in CEACAM1 Inactive Mice (Jan 2003). The 31<sup>st</sup> Annual Pharmacology Research Colloquium at the University of Michigan, Ann Arbor, MI

#### **POSTERS**

- 1- Gallemore, R.; Hudson, H.; Sharma, A.; Elman, M.; Wells, J.; **Al-Share, Q.**; Milton, M.; McBlane, F.; Li, Y.; Zamiri, P.; Grosskreutz, C. "A Proof-of-Concept Study of Intravitreal (IVT) LFG316 In Patients With Neovascular Age-Related Macular Degeneration (nAMD)". ARVO, Seattle, WA, May 2016.
- 2- Du, Y., Chandra, P., **Al-Share, Q.**, Jordaan, P., Langenickel, T., Pal, P., Sunkara, G., Mangold, J. and Flarakos, J. "An open-label, single dose study to investigate the absorption, distribution, metabolism, and

- elimination of [ $^{14}\text{C}$ ]-LCZ696 and its metabolites in healthy male subjects". AAPS, San Antonio, TX, Nov 2013.
- 3- **Al-Share, Q.Y.**, Jusko, W.J., Blum, R.A., Dandona, P., and Mager, D.E. Anti-Inflammatory Effects of Insulin as Compared to Four Systemic Corticosteroids. ASCPT, Atlanta, GA, March 2010.
  - 4- Patel, P.R., **Al-Share, Q.Y.**, Fernstrom, M.A., and Najjar, S.M. Free Fatty Acid Regulation of Hepatic CEACAM1 (2008). Bridging Graduate Studies at the University of Toledo. Graduate Student Research Forum, Toledo, OH
  - 5- Patel, P.R., **Al-Share, Q.Y.**, Fernstrom, M.A., and Najjar, S.M. Free Fatty Acid Regulation of Hepatic CEACAM1 (2008). Annual Pharmacology Colloquium. University of Michigan, Ann Arbor, MI
  - 6- TA Bowman DPM, **QY Al-Share** PhD, AM DeAngelis PhD, S Ghosh, PR Patel and SM Najjar PhD. CEACAM1 Repression as an Obligate Step in the Development of Diet-Induced Insulin Resistance. (The Endocrine Society's 92nd Annual Meeting, June 19–22, 2010 - San Diego)
  - 7- Lee, A.D., Ghosh, S., **Al-Share, Q.Y.**, Cicila, G.C., and Najjar, S.M. (2007) Exercise training increases hepatic CEACAM1 expression. The Experimental Biology Meeting. Washington. D.C
  - 8- Schroeder-Gloeckler, Jill; Deangelis, Anthony; Tong Dai; Heinrich, Garrett; **Al-Share, Qusai**; Sang Jun Lee; Dai Young Jung; Zhiyou Zhang; Eun-Gyoung Hong; Kim, Jason; Najjar, Sonia. Role of CEACAM2 in Insulin Action. (*Diabetes Jun 2007*).
  - 9- Deangelis, A.M., Yang, Y., Fernstrom, M.A., Abou-Rjaily, G.A., Lee, S.J., **Al-Share, Q.Y.**, Miller, T., Ruch, R.J., Smith, S., Lin, S.H., Beauchemin, N., Oyarce, A.M., and Najjar, S.M. (2005). Insulin Acutely Decreases Fatty Acid Synthase Activity by Inducing CEACAM1 Phosphorylation. The Endocrine Society 87<sup>th</sup> Annual Meeting, San Diego, CA
  - 10- **Al-Share, Q.Y.**, Rezaei, K., DeAngelis, A.M., Lee, S.-J., Fernström, M.A., Abou-Rjaily, G.A., Garofalo, R.S., and Najjar, S.M. (2005) Reduction of hepatic CEACAM1 levels: A Mechanism of Insulin Resistance Induced by High-fat Diet. The Endocrine Society 87<sup>th</sup> Annual Meeting. San Diego, CA
  - 11- **Al-Share, Q.Y.**, Rezaei, K., Lee, S.J., Fernström, M.A., DeAngelis, A.M., Garofalo, R.S., and Najjar, S.M. (2005) Reduction of Hepatic CEACAM1 Levels: A Mechanism of Insulin Resistance Induced by High-fat Diet. The 20<sup>th</sup> Annual Research Forum Sponsored by the Graduate School. Medical University of Ohio, Toledo, OH
  - 12- **Al-Share, Q.Y.**, and Najjar, S.M. (2004). High-fat Diet Decreases CEACAM1 Levels in Liver. The 19<sup>th</sup> Annual Research Forum Sponsored by the Graduate School at Medical University of Ohio, Toledo, OH

## **ABSTRACTS**

1. Saja S. Khuder, Lucia Russo, Sadeesh Kumar Ramakrishnan, **Qusai Al-Share**, Garrett Heinrich, Sang Jun Lee, Terry D Hinds, Brahma Raju Mopidevi, Yatrik Madhukar Shah, Edwin Ramon Sanchez and Sonia Michael Najjar. Regulation of CEACAM1 By Ppara-Dependent Mechanisms. (Endocrine Society's 96th Annual Meeting and Expo, June 21–24, 2014 – Chicago), accepted for oral presentation
2. Sadeesh Kumar Ramakrishnan DVM, Payal R. Patel BS, **Qusai Y. Al-Share** PhD, Thomas A. Bowman DPM, Sumona Ghosh BS, Yatrik M. Shah PhD, Edwin R. Sanchez PhD and Sonia M. Najjar PhD. (The Endocrine Society's 92nd Annual Meeting, June 19–22, 2010 - San Diego), Accepted for oral presentation
3. Tjonna, A.E., Haram, P.M., Lee, S.J., Stolen, T., Kemi, O.J., Bye, A., Loennechen, J.P., Rognmo, O., **Al-Share, Q.Y.**, Slordahl, S.A., Smith, G.L., Najjar, S.M., Wisloff, U. Superior Cardiovascular Effect of Interval Training Versus Moderate Exercise in Patients with Metabolic Syndrome. Med Sci sports Exerc. May; 39 (5 Suppl): s 173. The 54<sup>th</sup> annual meeting of American College of Sports Medicine (ACSM), New Orleans, Louisiana, May 30, 2007
4. Lee, A.D., Ghosh, S., **Al-Share, Q.Y.**, Cicila, G. C., and Najjar, S.M. Exercise training increases hepatic CEACAM1 expression. (*The FASEB annual meeting, Mar 2007*)
5. DeAngelis, T.A., Yang, Y., Fernström, M.A., Abou-Rjaily, G.A., Lee, S.-J., **Al-Share, Q.Y.**, Miller, T., Ruch, R.J., Smith, S., Lin, S.-H., Beauchemin, N., Oyarce, A.M., and Najjar, S.M. (2005) Insulin acutely

- decreases fatty acid synthase activity by inducing CEACAM1 phosphorylation. The Endocrine Society 87<sup>th</sup> Annual Meeting. San Diego, CA
6. **Al-Share, Q.Y.**, Rezaei, K., DeAngelis, A.M., Lee, S.-J., Fernström, M.A., Abou-Rjaily, G.A., Garofalo, R.S., and Najjar, S.M. (2005) Reduction of hepatic CEACAM1 levels: a mechanism of insulin resistance induced by high-fat diet. The Endocrine Society 87<sup>th</sup> Annual Meeting. San Diego, CA
  7. **Al-Share, Q.**, Rezaei, K., Dhindaw, S., Abou-Rjaily, G., Lee, S.J., Fernstrom, M., Deangelis, A., Garofalo, R., Najjar, S. (2004). CEACAM1: a Mechanism of Environmentally-induced Insulin Resistance. 12<sup>th</sup> International Congress of Endocrinology. Lisbon, Portugal, Aug 31-Sep 4, 2004
  8. **Al-Share, Q.Y.**, and Najjar, S.M. (2004). High-Fat Diet Decreases CECAM1 Levels in Liver. American Diabetes Association (ADA) annual meeting 64<sup>th</sup>, Orlando, FL